Back to results
US 2021/0172931 A1Published application
Large scale organoid analysis
AssigneeTempus Labs, Inc.
InventorsBrian M. Larsen, Michelle M. Stein, Luka A. Karginov, Ameen Salahudeen, Madhavi Kannan, Aly A. Khan, Verónica Sánchez Freire, Yilin Zhang
Life of this patent
Estimating the term…
Abstract
Methods, systems, and software are provided for using organoid cultures, e.g., patient-derived tumor organoid cultures, to improve treatment predictions and outcomes.
Claims31
A method of evaluating an effect of a therapeutic agent composition for a subject, the method comprising:
- A) exposing a plurality of tumor organoid subsets with a therapeutic agent composition comprising one or more therapeutic agents,
- wherein each of the tumor organoid subsets comprises a plurality of tumor organoids that are derived from one or more cells of a tumor biopsy from the subject, and
- wherein each of the subsets is exposed to a particular concentration of the therapeutic agent composition;
- B) obtaining a tumor organoid profile for each of the subsets in the plurality of subsets, wherein the tumor organoid profile comprises a cell viability value for each of at least five tumor organoids in each subset;
- and
- C) assessing the effect of the therapeutic agent composition based on the tumor organoid profiles.
3 more elements
A method for assigning a treatment dosage of a therapeutic agent composition for a patient having cancer, the method comprising:
- A) exposing a plurality of tumor organoid subsets to a therapeutic agent composition comprising one or more therapeutic agents,
- wherein each of the tumor organoid subsets comprises a plurality of tumor organoids that are derived from one or more cells of a tumor biopsy from the patient, and
- wherein each of the subsets is exposed to a different dosage of the therapeutic agent composition;
- B) obtaining a tumor organoid profile for each subset in the plurality of subset, wherein the tumor organoid profile comprises a cell viability value for at least five tumor organoids in the sub set;
- C) determining a therapeutic agent composition dosage curve from the tumor organoid profiles;
- and
- D) assigning a treatment dosage of the therapeutic agent composition to the patient based on the therapeutic agent dosage curve.
4 more elements
-117. (canceled)
Dependencies are inferred from the claim text.